Hutchmed Files For Over $600M Hong Kong IPO
Hutchmed (China) Limited (NASDAQ:HCM) will look to raise $603 million as part of a Hong Kong IPO, listed in the…
Roche’s New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod
The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG’s (OTC:RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the…
Bristol Myers Onureg Scores European Approval As Maintenance Therapy For Acute Myeloid Leukemia
The European Commission has granted full marketing authorization to Bristol Myers Squibb & Co’s (NYSE:BMY) Onureg (azacitidine tablets) The approval comes as…
Senator Joe Manchin Urges President Biden Not To Nominate Janet Woodcock As FDA Commissioner
While Senator Joe Manchin has been vocal on his opposition to Janet Woodcock as Biden’s choice for FDA…
Court Rules In Favor Of AstraZeneca Over Delay In COVID-19 Shot Deliveries
AstraZeneca Plc (NASDAQ:AZN) claims victory in a court tussle with the European Union over allegations that the company was not producing…
Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration
Iveric Bio Inc (NASDAQ:ISEE) has shared the new post-hoc analyses of GATHER1 and the progress of GATHER2 clinical trials evaluating Zimura…
AnPac Bio-Medical Stock Moves Higher On First Disease Treatment US Patent
AnPac Bio-Medical Science Co Ltd (NASDAQ:ANPC) has received its first disease treatment patent by the United States Patent and Trademark Office.…
Scholar Rock To Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic And Pharmacodynamic Data At 2021 European Academy Of Neurology Congress Jun. 19-22
Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced an oral e-presentation of
Edesa Biotech Announces An Independent Data And Safety Monitoring Board Has Completed Interim Review Of Co.’s COVID-19 Candidate And Recommended Study Continue As Planned
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an independent Data and Safety Monitoring Board (DSMB) has completed
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)